The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning about the risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep sedation. This drug class, involving injectable and oral medications used for ...

However, delayed gastric emptying could theoretically increase the risk for pulmonary aspiration during general anesthesia or deep sedation, a risk that the EMA described as "biologically plausible." ...

The most severe clinical problem which coexist with the meconium aspiration syndrome/MAS/is persistent pulmonary hypertension/PPHN/. The aim of our study was to evaluate the efficacy of treatment of ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. There was also no significant difference in the odds of acute respiratory failure.